6315-S (FLOMOXEF), A NEWLY SYNTHESIZED OXACEPHEM, IN UROLOGY
スポンサーリンク
概要
- 論文の詳細を見る
6315-S (flomoxef), a newly synthesized oxacephem, was evaluated in the urological field. The MICs of 6315-S against 18 reference strains and 188 clinical isolates from the urinary tract showed strong antibacterial activity against both Gram-positive and-negative bacteria except for<I>E. faecalis</I>and<I>P. aeruginosa</I>. Serum levels in patients with chronic renal failure were serially determined by bioassay. Serum levels of 6315-S after 0.5g and 1g injection were very high even on the second day. The elimination rate by hemodialysis was about 80%. We consider that a low dose such as 0.5g administered every other day would be suitable in the treatment of these patients. In a continuous ambulatory peritoneal dialysis (CAPD)-patient, as much as 16% of 6315-S was detected in the dialysate in 24 h, suggesting that this drug would be useful against peritonitis occurring in such patients, by helping prevent the spread of infection due to persisting high serum levels. Seventeen patients with complicated urinary tract infections (UTI) were injected with 1g of 6315-S twice a day for 5 days. Of these, 14 cases were evaluable according to the criteria proposed by the Japanese UTI Committee. Overall clinical efficacy was 43%. In catheterized patients or cases of polymicrobial infection, the drug proved less effective.<I>E. faecalis</I>was eradicated, despite of<I>in vitro</I>study, but 6315-S was not effective against<I>P. aeruginosa</I>which agreed with basic studies. We observed no subjective or objective side-effects. These results suggest that 6315-S is useful and safe in urinary tract infections, with the exception of infections caused by<I>P. aeruginosa</I>.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.